The Silent Partner: Why Logistics is the Most Critical Component of Your Next Clinical Trial
This article is directed at pharmacists, prescribers, hospital procurement teams, and accredited healthcare facilities. It does not constitute advice to individual patients or consumers. When a trial closes, the supply obligation does not. Patients on continued access need the same standard of supply as they received during the trial itself. That is where most programmes quietly struggle. Phase 4 and post-trial supply carry identical regulatory obligations to earlier-phase work. The difference is they run longer, across more dispersed sites, with less dedicated oversight. The logistics partner that managed the trial is often not configured for what comes next.
The post-trial supply gap
Continued access in Australia operates through the Special Access Scheme, compassionate supply or named-patient pathways, all under TGA oversight. HL Pharma refers to these collectively as a Managed Access Programme. Each requires an Australian Sponsor or Importer of Record, ongoing importation, validated storage and distribution, and pharmacovigilance support. HL Pharma provides this from trial close-out through to long-term access, covering post-trial drug retention, reverse logistics, reconciliation and TGA pathway support.
Phase 4: the same standards, a harder operating environment
Sites are community hospitals, regional clinics and GP practices. Many have no validated storage on site and no prior experience of clinical supply. Stock needs to reach them reliably, with cold-chain integrity and documentation that will hold up to audit years later.
Common failure points:
• Cold-chain excursions in transit to sites without validated receiving capability
• Import documentation gaps causing delays on restocked batches
• Stock shortfalls when re-supply is not triggered against real patient demand
• Batch and retention records falling out of order over a multi-year programme
• Reverse logistics and close-out documentation not managed to the required standard
One partner across the full pathway
HL Pharma acts as a single point of accountability: global sourcing, TGA sponsorship, importation, temperature-controlled storage, national distribution and pharmacovigilance, under one ISO 9001:2015-certified quality system. Our Melbourne facility operates as a regional depot for Australia, New Zealand and key Asia Pacific markets. We work alongside your CROs, regulatory consultants and safety partners so patients continue their therapy without interruption.
Where we can support you:
• Post-trial supply management: importation, storage, distribution and pharmacy dispensing for extension studies and continued access
• Permit support: biological import permits, controlled drug licences and regulatory paperwork
• TGA pathway advice: SAS, Authorised Prescriber and post-trial access routes
• Reverse logistics: return, reconciliation and destruction of unused trial materials
• Post-trial drug retention: secure, temperature-controlled storage after study completion
• Global medicine sourcing across Europe, the UK, India, the USA and beyond
• Temperature-controlled storage across CRT, refrigerated, frozen and ultra-low environments
• Schedule 8 and 9 vault storage with full ODC compliance
• Pharmacovigilance and TGA reporting support throughout the programme lifecycle
All delivered under our ISO 9001:2015-certified quality management system, aligned with GDP and GWP standards.
To discuss your Phase 4 study or post-trial access requirements, contact our team at hlpharma.com.au/contact/ or call +61 3 7036 0141.
HL Pharma supports the compliant management of medicine access pathways, regulatory sponsorship and continuity of supply for sponsors, CROs, manufacturers, hospitals, pharmacies and wholesalers across Australia and the Asia-Pacific region. This content describes HL Pharma’s services and is intended for industry and healthcare organisation audiences. It does not constitute regulatory advice or consumer information about specific therapeutic goods.